{"id":"liraglutide-pen-injector","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nausea"},{"rate":"5-15","effect":"Vomiting"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"10-20","effect":"Constipation"},{"rate":"5-10","effect":"Hypoglycemia"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4084119","moleculeType":"Protein","molecularWeight":"3751.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Liraglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also reduces glucagon secretion when blood glucose is elevated and delays gastric emptying, leading to reduced postprandial glucose excursions. These combined effects improve glycemic control and promote weight loss in patients with type 2 diabetes.","oneSentence":"Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:05.093Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Weight management in obese or overweight patients"}]},"trialDetails":[{"nctId":"NCT06976619","phase":"PHASE2","title":"The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-10-03","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":60},{"nctId":"NCT06171152","phase":"EARLY_PHASE1","title":"Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-01-26","conditions":"Multiple Sclerosis, Long COVID, Long Covid19","enrollment":30},{"nctId":"NCT03260881","phase":"PHASE4","title":"Liraglutide Effects on Epicardial Fat Inflammatory Genes","status":"COMPLETED","sponsor":"University of Miami","startDate":"2018-09-01","conditions":"Type2 Diabetes, Coronary Artery Disease","enrollment":38},{"nctId":"NCT03158805","phase":"PHASE2","title":"Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)","status":"COMPLETED","sponsor":"Lindner Center of HOPE","startDate":"2017-04-26","conditions":"Bipolar Disorder, Obesity","enrollment":60},{"nctId":"NCT06818292","phase":"NA","title":"Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists","status":"COMPLETED","sponsor":"Nils Opel","startDate":"2024-10-21","conditions":"Healthy","enrollment":10},{"nctId":"NCT04199728","phase":"PHASE1, PHASE2","title":"Use of a GLP-1R Agonist to Treat Opioid Use Disorder","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2021-10-18","conditions":"Opiate Substitution Treatment, Opioid-Related Disorders","enrollment":27},{"nctId":"NCT04763564","phase":"PHASE2","title":"Efficacy of Liraglutide Therapy in Patients With IPAA","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-03-22","conditions":"Pouchitis, Irritable Pouch Syndrome","enrollment":8},{"nctId":"NCT03856047","phase":"PHASE2","title":"Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-03-01","conditions":"Overweight, Obesity","enrollment":706},{"nctId":"NCT03795701","phase":"NA","title":"To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity","status":"COMPLETED","sponsor":"Texas Tech University","startDate":"2019-01-08","conditions":"Obesity","enrollment":73},{"nctId":"NCT04781998","phase":"PHASE4","title":"Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?","status":"COMPLETED","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2021-07-01","conditions":"Mental Disorder, Metabolic Disturbance, Feasibility","enrollment":24},{"nctId":"NCT05285397","phase":"NA","title":"Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.","status":"UNKNOWN","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","startDate":"2022-03-10","conditions":"Morbid Obesity","enrollment":60},{"nctId":"NCT03038620","phase":"PHASE4","title":"Impact of Liraglutide 3.0 on Body Fat Distribution","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-01","conditions":"Obesity, Visceral, Cardiovascular Diseases, Fat Disorder","enrollment":235},{"nctId":"NCT03480022","phase":"PHASE3","title":"Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS","status":"COMPLETED","sponsor":"Woman's","startDate":"2018-09-26","conditions":"Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android","enrollment":88},{"nctId":"NCT03347890","phase":"PHASE4","title":"Reward Mechanisms in Obesity","status":"COMPLETED","sponsor":"Zoltan Pataky","startDate":"2018-03-05","conditions":"Obesity","enrollment":70},{"nctId":"NCT04643301","phase":"NA","title":"Liraglutide for Low-responders After Bariatric Surgery","status":"WITHDRAWN","sponsor":"Zuyderland Medisch Centrum","startDate":"2020-12-21","conditions":"Obesity, Obesity, Morbid","enrollment":""},{"nctId":"NCT04057261","phase":"PHASE3","title":"Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease","status":"WITHDRAWN","sponsor":"RWTH Aachen University","startDate":"2020-11","conditions":"Type 2 Diabetes, Cardiovascular Diseases","enrollment":""},{"nctId":"NCT03341429","phase":"PHASE4","title":"Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response","status":"COMPLETED","sponsor":"University College, London","startDate":"2018-08-22","conditions":"Obesity","enrollment":70},{"nctId":"NCT03642600","phase":"PHASE4","title":"The Gut Microbiome in Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-02-28","conditions":"PCOS, Obesity, Metabolic Syndrome","enrollment":21},{"nctId":"NCT03371862","phase":"PHASE2","title":"Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2017-10-20","conditions":"Short Bowel Syndrome","enrollment":""},{"nctId":"NCT04373967","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-04-29","conditions":"Type 2 Diabetes","enrollment":424},{"nctId":"NCT04046822","phase":"PHASE4","title":"Effect of Liraglutide on Microbiome in Obesity","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2019-01-09","conditions":"Obesity, Weight Loss, Microbiome","enrollment":70},{"nctId":"NCT03421119","phase":"PHASE3","title":"Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes","status":"UNKNOWN","sponsor":"Cinnagen","startDate":"2019-06-20","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT03534310","phase":"NA","title":"Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2015-11-02","conditions":"Obesity","enrollment":75},{"nctId":"NCT01725126","phase":"PHASE2","title":"To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-10","conditions":"Obesity","enrollment":53},{"nctId":"NCT02207348","phase":"PHASE1","title":"Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":24},{"nctId":"NCT01175473","phase":"PHASE2","title":"Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-08","conditions":"Type 2 Diabetes Mellitus","enrollment":148},{"nctId":"NCT01596504","phase":"PHASE2","title":"Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Type 2 Diabetes Mellitus","enrollment":142},{"nctId":"NCT01733758","phase":"PHASE3","title":"A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02","conditions":"Diabetes Mellitus, Type 2","enrollment":494}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Victoza","Saxenda","Liraglutide","Placebo Saxenda","Placebo liraglutide 3 mg"],"phase":"phase_3","status":"active","brandName":"Liraglutide Pen Injector","genericName":"Liraglutide Pen Injector","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying. Used for Type 2 diabetes mellitus, Weight management in obese or overweight patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}